Branko Cuglievan
University of Texas MD Anderson Cancer Center
108 Papers
69 Citations
Branko Cuglievan is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 8, co-authored 32 publications. Previous affiliations of Branko Cuglievan include University of Texas at Austin & Boston Children's Hospital.
Chat about Author
Papers
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
Ghayas C Issa,Ibrahim Aldoss,John F. DiPersio,Branko Cuglievan,Richard Stone,Martha Arellano,Michael J. Thirman,Manesh R. Patel,David S. Dickens,Shalini Shenoy,Neerav Shukla,Hagop M. Kantarjian,Scott A. Armstrong,Florian Perner,Jennifer A. Perry,Galit Rosen,Rebecca G. Bagley,Michael O. Meyers,Peter Ordentlich,Yu Gu,Vinit Kumar,Steven Smith,Gerard McGeehan,Eytan M. Stein +23 more
TL;DR: In this paper , the first-in-human phase 1 clinical trial investigating revumenib (SNDX-5613), a potent and selective oral inhibitor of the menin-KMT2A interaction, in patients with relapsed or refractory acute leukaemia (ClinicalTrials.gov, NCT04065399).
Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival
Vivek Subbiah,Salah-Eddine Lamhamedi-Cherradi,Branko Cuglievan,Brian A. Menegaz,Pamela Camacho,Winston W. Huh,Vandhana Ramamoorthy,Peter M. Anderson,Raphael E. Pollock,Dina Lev,Wei Qiao,Mary Frances McAleer,Robert S. Benjamin,Shreyaskumar Patel,Cynthia E. Herzog,Najat C. Daw,Barry W. Feig,Alexander J. Lazar,Andrea Hayes-Jordan,Joseph A. Ludwig +19 more
TL;DR: Improved 3- and 5-year OS were observed following multidisciplinary treatment that includes Ewing sarcoma (ES)-based chemotherapy and complete tumor cytoreductive surgery, but few if any patients are cured.
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements.
Ghayas C. Issa,Jabra Zarka,Jabra Zarka,Koji Sasaki,Wei Qiao,Daewoo Pak,Daewoo Pak,Jing Ning,Nicholas J. Short,Fadi Haddad,Zhenya Tang,Keyur P. Patel,Branko Cuglievan,Naval Daver,Courtney D. DiNardo,Elias Jabbour,Tapan M. Kadia,Gautam Borthakur,Guillermo Garcia-Manero,Marina Konopleva,Michael Andreeff,Hagop M. Kantarjian,Farhad Ravandi +22 more
TL;DR: In this paper, the authors identified 172 adult patients with acute myeloid leukemia (AML) with rearrangement of the lysine methyltransferase 2a gene (KMT2Ar) and compared them to 522 age-matched patients with diploid AML.
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer
Dristhi Ragoonanan,Sajad Khazal,Hisham Abdel-Azim,David McCall,Branko Cuglievan,Francesco Paolo Tambaro,Ali Haider Ahmad,Courtney M. Rowan,Cristina Gutierrez,Keri Schadler,Shulin Li,Matteo Di Nardo,Linda Chi,Alison M. Gulbis,Basirat Shoberu,Maria E. Mireles,Jennifer McArthur,Neena Kapoor,Jeffrey Miller,Julie C. Fitzgerald,Priti Tewari,Demetrios Petropoulos,Jonathan Gill,Christine Duncan,Leslie Lehmann,Sangeeta Hingorani,Joseph Angelo,Rita D. Swinford,Marie E. Steiner,Fiorela N. Hernandez Tejada,Paul L. Martin,Jeffery J. Auletta,Sung Won Choi,Rajinder P.S. Bajwa,Natalie Dailey Garnes,Partow Kebriaei,Katayoun Rezvani,William G. Wierda,Sattva S. Neelapu,Elizabeth J. Shpall,Selim Corbacioglu,Kris M. Mahadeo +41 more
TL;DR: In this article, a consensus statement of the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network Hematopoietic Cell Transplantation-Cancer Immunotherapy (HCT-CI) Subgroup, Paediatric Diseases Working Party (PDWP) of the European Society of Blood and Marrow TransplantATION (EBMT), Supportive Care Committee of the pediatric Transplant and Cellular Therapy Consortium (PTCTC) and MD Anderson Cancer Center CAR T Cell Therapy-associated Toxicity (CARTOX) Program
IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers
Hesham M. Amin,Ajaykumar C. Morani,Najat C. Daw,Salah Eddine Lamhamedi-Cherradi,Vivek Subbiah,Brian A. Menegaz,Deeksha Vishwamitra,Ghazaleh Eskandari,Bhawana George,Robert S. Benjamin,Shreyaskumar Patel,Juhee Song,Alexander J. Lazar,Wei Lien Wang,Razelle Kurzrock,Alberto S. Pappo,Peter M. Anderson,Gary K. Schwartz,Dejka M. Araujo,Branko Cuglievan,Ravin Ratan,David McCall,Sana Mohiuddin,John A. Livingston,Eric R. Molina,Aung Naing,Joseph A. Ludwig +26 more
TL;DR: Synergistic drug combinations, and newly identified proteomic or radiological biomarkers of IGF-1R response, may be incorporated into future IGF- 1R-related trials to improve the response rate in ES patients.
29